BNET Industries
Market Cap:$104.0B
Last Fiscal Year Sales:$32.9B
- Public
- FR
Dow Jones Description
Sanofi-Aventis sees the future - where disease is in the past. Formed by a 2004 merger and headquartered in Paris, France, Sanofi-Aventis (NYSE: SNY (ADR) Euronext Paris: SAN) is the third-largest pharmaceutical maker in the world. The company researches, develops, manufactures, and markets prescription drugs. Its products include Allegra, Aprovel, Eloxatin, Lovenox, Nasacort, Plavix, Taxotere, and Tritace, among others. It has over 100 compounds in development, about 40 of which are in Phase II or III clinical trials. The company has annual revenue of about A28.5 billion and employs about 100,000 people. In March 2006 the company acquired almost 25% of Zentiva NV for approximately A430 million. In 2005 the company sold its interests in Wacker-Chemie.
Number of Employees 97,181
Peer Companies
NAICS Code Drugs and Druggists' Sundries Merchant Wholesalers: 424210
Recent Events
-
Sanofi-Aventis SNY Announces Agreement with Intelliject for Novel Epinephrine Auto Injector
-
The Side Effect of Developing Obesity Drugs
-
Drugmakers' Differences: Analyst's Toolkit
-
Deutsche Bank Initiates Coverage on Sanofi-Aventis SNY with a Buy
-
Big Pharma Willing to Pay for Biotech Innovation
-
Sanofi-Aventis names Spek global operations head 37 mins ago
-
Sanofi-Aventis Q3 Profit Rises; Lifts FY09 Adj. EPS Growth View; To Buy Laboratoire Oenobiol -...
-
UPDATE 3-Sanofi lifts forecast on swine flu vaccine
-
Sanofi-Aventis and Micromet to Develop New Tumour Antibody
-
Dyax Corp. Q3 2009 Earnings Call Transcript
-
Sanofi-Aventis's New JV Will Provide Entry into Chinas OTC Market
-
Mexico pushing for homegrown swine flu vaccine
-
Sanofi cozies up to Wellstat for $350M diabetes insulin pact
-
Sanofi-Aventis France (SASY.PA) Buys Wellstat Therapeutics Corporation's Type II Diabetes Drug PN2034 For Up To...
-
Wellstat Therapeutics and Sanofi-aventis Enter Agreement On Novel Therapy for Type II Diabetes
-
Notable Analyst Rating Changes 10/14: CSC, GSK, SNY, ABX, CNO, HOG, TEL Upgrade; VLO, JBLU,...
-
Sanofi-Aventis France (SASY.PA) to Buy Dyax Corp. DYAX's Drug Development Partner, Fovea Pharmaceuticals
-
BRIEF-Credit Suisse raises targets on European pharma cos
-
Sanofi to launch own generic version of Plavix
News & Analysis
Filter by
healthcare and sanofi-aventis - All News and Analysis
Big Pharma Pipeline: Why So Dry?
Saj Karsan submits: Pharmaceutical companies are trading well below their historical P/E levels. To anyone who follows the industry, this comes as no surprise. After a slew of blockbuster drugs that hit the market several years ago, the R&D departments of the largest companies have been coming up empty as...
Time to Invest in Pharmaceuticals?
Howard Sun submits: The prices of many pharmaceutical companies have been beaten down by Wall Street in recent months. With companies like Pfizer PFE, Schering-Plough SGP and Bristol-Myers Squibb BMY reaching lower lows, one has to wonder when the pain will end as these companies are now significantly undervalued. The...
Four Drug Companies Vying for Diabetes Patients
R.J Steffens submits: The American Association of Diabetes Educators [AADE] released results last week at its high profile 35th Annual Meeting from an innovative new survey entitled the "Injection Impact Report". The report highlights the level of communication between patients and healthcare providers relating to insulin injections and...
Generic Drugs: Industry Snapshot
Mike Havrilla submits:Global Generic Drug Industry: Benchmark Comps Global Generic Drug Industry: Top 5 Companies by Market Cap Global Generic Drugs: Top 5 Companies by Stock Performance The accompanying tables provide a snapshot of my 38-company Global Generic Drug Index, which is rapidly consolidating amidst a flurry of recent M&A activity --...
FDA Calendar: Cardiome, Momenta, Discovery Labs, Introgen
Mike Havrilla submits: click to enlarge by Mike Havrilla
Cel-Sci Shares Jump After Bird Flu Vaccine Enhancer Assertion.
M2 PRESSWIRE-5 April 2006-SessionsIR.com: Cel-Sci Shares Jump After Bird Flu Vaccine Enhancer AssertionC1994-2006 M2 COMMUNICATIONS LTD RDATE:05042006 Stocks in the News: CalbaTech, Inc. (OTC: CLBE), StemCells Inc. (NASDAQ: STEM), Geron Corporation (NASDAQ: GERN), Cel-Sci Corp. (AMEX: CVM), Sanofi Aventis AS (NYSE:...
France's Sanofi-Aventis to produce H5N1 vaccine
PARIS AFP — French pharmaceutical group Sanofi-Aventis said it has agreed to produce 1.4 million doses of a prototype vaccine for humans to treat the strain of bird flu known as H5N1 which has killed more than 60 people in Asia. A spokesman for the company said the deal...
- 1
| Volume | 1,451,324 |
| Shares Outstanding | 2.6B |
| Market Cap | 104.0B |
| Year High | 40.17 |
| Year Low | 24.59 |
| Earnings Per Share | 2.21 |
| P/E Ratio | 17.8914 |
| Dividend | 1.0639 |
| Yield | 2.69 |
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
Glass Door
Sanofi-Aventis
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes

